1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2026

Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2026

  • February 2018
  • 319 pages
  • ID: 5404418
  • Format: PDF
  • By GlobalData

Summary

Table of Contents

Search Inside

Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2026

Summary
Age-related macular degeneration (AMD) (ICD-10: H35.3) is one of the leading causes of vision loss among persons ages 50 years and over in developed countries and is the third leading cause of vision loss worldwide, after cataract and glaucoma (WHO, 2017). The exact cause of AMD is unknown; however, age is a major risk factor of AMD.

There are two major forms of AMD; “dry” (dAMD; nonexudative or atrophic) and “wet” (wAMD; exudative or neovascular) AMD. AMD is characterized by progression from early to intermediate and subsequently to the two major advanced forms of dAMD and wAMD: geographic atrophy (GA) and choroidal neovascularization (CNV), respectively.

The AMD market is about to enter an exciting phase over the next decade with the arrival of three novel therapies for dAMD, as well as the launches of two longer-duration anti-VEGF therapies and one adjunctive therapies to anti-VEGF for the treatment of wet AMD (wAMD). The AMD market is expected to increase from around $4.9B to $11.5B over the 10-year forecast period from 2016-2026. The launch of new drugs in both dAMD and wAMD will drive a significant market growth and the rapidly aging population will contribute to this growth. The population of wAMD patients in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) covered in this report is expected to increase from 1.8 million people in 2016 to 2.4 million in 2026. GlobalData estimates the number of dry AMD (dAMD) patients with the late stage of the disease, called geographic atrophy (GA), at 1.5 million, which will increase to 2.1 million by 2026.

The major drivers of growth in the AMD market during the forecast period include -
- New product launches will be strong drivers in both the wAMD and dAMD markets.
- The availability of therapies for GA will drive a sustained increase of treated GA cases, expanding this market.
- The aging populations in the 7MM will contribute to the growth of AMD markets, together with an expected increase in the diagnosis of the disease.
- The high annual cost of therapy (ACOT) for pipeline drugs means they will generate high sales and drive growth, curtailing the impact of the expiring patent protections of current therapies.

The report "Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2026", provides overview Overview of AMD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

In particular, this report provides the following -
- Annualized AMD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (GA due to dry AMD and wet AMD), forecast from 2016 to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AMD therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for AMD therapy. The most promising candidates in Phase IIb and Phase III developments are profiled.
- Analysis of the current and future market competition in the global AMD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: Roche, Genentech, Novartis, Alcon, Regeneron, Bayer, Valeant, Allergan, Ohr, Ophthotech, Apellis, Opthea, Chugai, Pfizer, Santen, PanOptica, SciFluor Life Sciences, Tyrogenex, RXi Pharmaceuticals, Janssen, Astellas Pharma

Scope
- Overview of AMD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized AMD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (GA due to dry AMD and wet AMD), forecast from 2016 to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AMD therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for AMD therapy. The most promising candidates in Phase IIb and Phase III developments are profiled.
- Analysis of the current and future market competition in the global AMD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global AMD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AMD therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
30% Off

($10995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Amyloidosis - Pipeline Review, H1 2020

Amyloidosis - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

Amyloidosis - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Amyloidosis - Pipeline Review, H1 2020, provides an overview of the Amyloidosis (Metabolic Disorders) ...

Macular Edema - Pipeline Review, H2 2019

Macular Edema - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Macular Edema - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema - Pipeline Review, H2 2019, provides an overview of the Macular Edema (Ophthalmology) ...

Axial Spondyloarthritis - Pipeline Review, H2 2019

Axial Spondyloarthritis - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Axial Spondyloarthritis - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Axial Spondyloarthritis - Pipeline Review, H2 2019, provides an overview of the ...

Uveitis - Pipeline Review, H2 2019 $ 2000 November 2019


ref:plp2018

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on